At a glance
- Originator Mitsubishi Pharma Corporation
- Class Anti-inflammatories
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 26 Aug 2006 No development reported - Preclinical for Inflammation in Japan (PO)
- 31 Mar 2003 Preclinical trials in Inflammation in Japan (unspecified route)